webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Mal-C2-Gly3-EDA

  CAS No.:   Cat No.: BADC-01269   Purity: ≥95% 4.5  

Mal-C2-Gly3-EDA is a cleavable ADC linker containing a Maleimide group. Mal-C2-Gly3-EDA is used for making antibody-drug conjugate.

Mal-C2-Gly3-EDA

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C15H22N6O6
Molecular Weight
382.37
Shipping
Room temperature
Storage
Store at -20 °C, keep in dry and avoid sunlight.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Solubility
10 mm in DMSO
Shelf Life
0-4°C for short term (days to weeks), or -20°C for long term (months).
Shipping
Room temperature
Storage
Store at -20 °C, keep in dry and avoid sunlight.

Mal-C2-Gly3-EDA is a versatile compound widely used in the field of bioconjugation, particularly for the modification of biomolecules such as proteins, peptides, and nucleic acids. The structure of Mal-C2-Gly3-EDA consists of a malonic acid group, a glycine linker (Gly3), and an ethylenediamine (EDA) moiety, which enables the conjugation of the compound to various biomolecules via amine-reactive chemistry. The malonic acid group provides a convenient site for chemical modification, while the glycine spacer enhances flexibility and minimizes steric hindrance during conjugation. This makes Mal-C2-Gly3-EDA an ideal tool for developing stable conjugates for therapeutic and diagnostic applications.

A key application of Mal-C2-Gly3-EDA is in the development of targeted drug delivery systems. The compound can be conjugated to drugs, antibodies, or other targeting moieties, forming a prodrug or drug conjugate that can specifically bind to diseased cells, such as cancer cells, through a biomolecular target. The ethylenediamine linker in Mal-C2-Gly3-EDA allows for efficient coupling to amine-functionalized molecules, enhancing the precision of drug delivery. By conjugating cytotoxic agents or therapeutic proteins to the Mal-C2-Gly3-EDA linker, drugs can be directed to tumor sites, thereby reducing systemic toxicity and improving therapeutic efficacy. This application is particularly useful in the creation of antibody-drug conjugates (ADCs) and other targeted therapies.

Mal-C2-Gly3-EDA is also used in the synthesis of peptide-based biomaterials and scaffolds. The flexibility provided by the glycine spacer, combined with the amine-reactive ethylenediamine group, allows for the precise assembly of complex peptide constructs. These constructs can be used for a variety of purposes, including tissue engineering, drug delivery, and the creation of bioactive surfaces. In particular, Mal-C2-Gly3-EDA is useful for creating functional peptide coatings on nanoparticles or other delivery systems, improving their stability, biocompatibility, and targeting capabilities. This application holds promise for advancing the development of peptide-based vaccines, diagnostic devices, and personalized therapeutics.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: DBCO-SS-PEG4-Biotin | DBCO-(PEG2-Val-Cit-PAB)2 | Fmoc-Gly-Gly-D-Phe-OtBu | t-Boc-N-amido-PEG6-propionic acid | APN-PEG4-Amine hydrochloride | Boc-amino-PEG3-SSPy | Aminooxy-PEG2-bis-PEG3-DBCO | DBCO-PEG4-SS-TCO | Mc-Leu-Gly-Arg | Hydroxy-PEG3-DBCO | Mal-C2-Gly3-EDA
Send Inquiry
Verification code
Inquiry Basket